New drug duo aims to outperform standard pill for common lung cancer
NCT ID NCT06838273
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding an experimental IV drug called BL-B01D1 to the standard pill osimertinib works better than osimertinib alone for people with advanced EGFR-mutated non-small cell lung cancer. About 720 participants will be randomly assigned to one of the two treatment groups. The main goal is to see if the combination delays cancer growth longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug given by IV) combined with osimertinib (a daily pill)
What this could lead to
If successful, this combination could become a new first-line treatment option that delays cancer progression longer than osimertinib alone for people with EGFR-mutated lung cancer.
What could go wrong
This is an early-phase 3 trial, so results are not yet known. The combination may cause more side effects than osimertinib alone, and it might not improve survival or quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact